#Hurricane Isaac Lands on Katrina Eve; Nuclear plant Shutting as Isaac Precaution; Isaac Battering Gulf coast with Fierce Winds Heavy<Head:
Hurricane Isaac Lands on Katrina Eve; Nuclear plant Shutting asisaac Precaution; Isaac Battering Gulf coast with Fierce Winds Heavyrains;
Water Overtopping Levee in Plaquemines Parish Louisiana-Part 1><Byline: Connell Mcshane Lori Rothman Cheryl Casone Nicole Petallidesjeff Flock Maria Molina Sandra Smith Jennifer Davis Phil Keating<Guest:
Steve Chabot Jeff Atwater Peter Wallison; Joshua Raymond Chip<Spec: Business; Stock markets; Storms; Politics>JONATHAN SERRIE FOX NEWS CORRESPONDENT:
At least I'm not feeling it in the eyes. And that certainly makes things a lot safer.
So we appreciate Ron (ph). CONNELL MCSHANE FOX BUSINESS ANCHOR: You've been watching it live.
Hurricane Isaac making landfall pounding parts of the Gulf coast with 80 mile-an-hour winds heavy rain.
And really the news of the moment here is this terrifying hurricane in the Gulf coast.
In the meantime let's update you on the markets especially overseas Asian European futures as well as commodities hopefully we can show you.
The breaking news Lori this morning Hurricane Isaac beginning to move inland through Southeast Louisiana now
when these satellite trucks as we say take a hit from time to time. Jeff Flock's shot just went down. Normally what happens is it will come back up here in a minute
if that is an army corps of engineer levee or that's an actual local levee that is felt in that parish.
We are still looking at a hurricane with maximum sustained winds of 80 miles per hour. We continuously receive updates from the National Hurricane Center
and obviously much more often today because the system is making landfall. It did make landfall one landfall yesterday evening as a category one hurricane across Southeastern Louisiana.
We saw a second landfall at about 2: 15 Central time early this morning across Southeastern Louisiana as well.
and some of the strongest winds associated with Hurricane Isaac right now pushing into that city with that--the reason for that is that we have the eye wall moving inland now.
So we are expecting Isaac to remain a hurricane throughout the rest of this morning possibly weakening into a tropical storm as we head into later afternoon hours.
or whether Isaac is a hurricane or a tropical storm. The big story is how slow it's moving.
So take a look of the track by Wednesday 1 p m. still a category one hurricane with maximum sustained winds of 75 miles per hour One of the reasons why it's going to take longer to weaken that most typical land falling storms is that we have swampland
And the other big story or the reason why Isaac should be slow to weaken is it is such a large storm system those tropical storm force winds to extend upward from the center of the storm up to 175 miles hurricane force winds up to
As Maria is reporting the worst with Hurricane Isaac maybe still ahead. Well keep in track.
And Connell looking at some more reports right now it looks like at this point there were earlier reports that people were trapped in the attic of their home because of the rising waters.
which unbelievable the coincidence of the anniversary of Katrina here with now Hurricane Isaac barreling virtually the same track.
Meantime the hurricane forcing the closure of a nuclear power plant this morning in Louisiana as well. Entergy Corporation saying it shut down of its plants in Colona (ph) Louisiana about 20 miles west of New orleans as a precaution.
The two others remain in operation at this point. Entergy saying the plant which is designed to sustain winds up to 200 miles an hour
if it had to will be powered up after the storm passes. So that's where we are.
And it will have certainly an impact on production oil production in the gulf the hurricane will.
And that could mean higher prices at the pump. They have been going up any way and Sandra Smith has the latest from the Newsroom this morning.
and through the Southeast of United states. The hurricane we do know forced more than 93 percent of oil production to shut down in the region
But overall somewhat mixed trading as far as the energy prices are concerned. Getting back to those gas prices analysts are predicting that we could see a ten-cent spike of gasoline prices as we see the effects of the storm play out depending on how drastic the supply cut actually is from the region
and how long it actually lasts. But if it doesn't last analysts are also forecasting a quick retreat from that possible spike in gasoline prices.
So that's the latest from here. Back to you guys. PETALLIDES: Thank you Sandra. So she's following oil for us.
Of course we'll continue to follow Hurricane Isaac closely for you. But now we're going to just take a look here at politics.
One of the two breaking stories we're following this morning along with the hurricane. But the earnings alert that we're seeing coming in right now real quick for you is from Joy Global the mining equipment company passing along a report of adjusted profit of $1. 82.
It missed the estimate by a bit there. The estimate was $1. 88. Revenue is 1. 4 billion--1. 42 billion.
So just so you know Joy Global out with earnings. Now more on the European markets this morning.
so focused obviously on this hurricane political conventions and everything else. But tell us what you make of the markets this morning?
and measures that they may be taking from the Fed in terms of more stimulus and quantitative easing. RAYMOND:
And now for a closer look at the Asian markets Katie Sargent joins us he is on the telephone from Singapore.
Shares in Renesas Electronics that helped that index those were up 35 percent on reports that a private equity firm KKR plans to invest nearly $1. 3 billion in the company.
Also we saw Sharp corporation up seven percent after it said it would offer severance packages to hundreds of workers as it restructures.
Samsung Electronics was a strong performer there of nearly three percent recouping some of the losses that it suffered after its legal loss to Apple.
and a half years weeks corporate profits report are polling that index lower. But overall sort of lackluster day.
So we are keeping an eye on Ford right here at home Ford obviously an automaker
because they pushed the Aston martin Jaguar land rover Volvo. However they haven't pushed the Lincoln brand.
And those are names that will be reporting quarterly numbers including Zales Jewelers that will be one to watch as well as Heinz and Payless Shoe store Parent
A few thoughts here for the same Zales comes on the heels of Movado and Tiffany which both some good outlook.
Great outlook there. So we've already seen Zales on the upside as well. And Heinz we've already got the glimpse from at the CEO yesterday just talking about emerging markets and growth there for the catsup company.
So Heinz looking like one to watch certainly and sounding like they have some good news ahead for us.
So those will be some hot stocks to watch. That's the latest. Now over to Cheryl Casone.
and we're looking at lot of economic data that's going to becoming out today including this should be interesting the second reading on growth for the second quarter.
Economists are expecting that that reading is going to climb a little bit any way 1. 7 percent from the first
And then the fun continues 2 p m. the Federal reserve going to unveil you can't wait for it the latest report on economic conditions.
whether policy-makers at the Central bank are thinking of implementing stimulus measures. And Wellpoint CEO Angela Braly has resigned from pressure from investors and shareholders.
The company's board said it will begin searching for a permanent replacement but executive vice president and General Counsel John Cannon is going to serve at this point as the interim chief of the company.
And some major Wellpoint investors expressed concern about Braly's leadership and her company strategy after disappointing second quarter results.
And then Apple is going to have to wait at this point until December to find out
whether its request for a sales ban against eight Samsung devices is going to be granted. A U s. judge has set a December 6 court date to consider a permanent injunction which could delay the potential impact of a legal victory.
Apple was awarded just over $1 billion last week after a California jury found that Samsung had copied critical features of the iphone and the ipad.
Apple now seeking to have pulled eight devices from U s. store shelves including the very popular very very popular galaxy smart phones.
A lot of people actually like those smart phones but this was such Connell such a big you know victory for Apple.
But the breaking story of the morning is Hurricane Isaac as it pounds the city of New orleans. Jeff Flock is on the scene there.
The findings of a new study have advanced significantly researchersknowledge of immunity for these pathogens. Information about the immune responses that occur in animals following haemoplasma infection is relatively unknown largely due to the fact that researchers struggle to study these bacteria as they are unable to grow them in the laboratory.
Antibiotics do not consistently clear infection and without correct treatment the anaemia can be fatal.
Recently haemoplasma associated anaemia has been reported in a human too. The aim of the study was to determine
whether cats who had recovered previously from M. haemofelis infection were protected from re-infection. The researchers found that they were representing a significant advancement in scientistsknowledge of immunity for haemoplasmainfections.
The exact methods of protective immunity could not be identified clearly despite extensive investigations but the study results suggest that a vaccine using a weakened form of the bacteria may offer protection against haemoplasma infection.
Dr Séverine Tasker Reader in Feline Medicine in Companion Animal Studies who led the study said:
his is the first study to demonstrate protective immunity against M. haemofelis reinfection and it provides important information for a possible future hemoplasma vaccine. ur findings could help prevent the disease in cats
and could also be of particular importance to farm animal species where haemoplasma infections can cause huge financial losses. he study recommends future research should explore
whether the bacterial animal infection could be transmitted to humans and how the immune system targets the pathogen t
#California Unveils Strictest Rules on Pesticide California farmers now must abide by the nation's strictest rules for a widely used pesticide in a change designed to protect farmworkers
and people who live and work near agricultural fields but is likely to raise prices on produce.
The restrictions announced Wednesday target chloropicrin, a pesticide injected into the ground before planting crops such as strawberries, tomatoes and almond orchards.
In recent years, the chemical has caused hundreds of people to suffer from irritated eyes, coughing fits and headaches,
state officials said. The new regulations surpass standards required by U s. Environmental protection agency. Brian Leahy director of the California Department of Pesticide regulation, said Tuesday that the higher standard is needed in California, the nation's leading agricultural producer and most populated state,
where farms are often next to people. Costs are sure to rise for farmers, who will pass it along to consumers,
but Leahy said it is worth it.""It is said burdensome, "Leahy.""But if we're going to use these tools,
we've got to ensure that they're used as safely as possible.""Under the new regulation, farmers are limited to applying the pesticide on up to 40 acres in one day, a reduction of 75 percent.
It also expands the distance between fields and human activity-in some cases to double the distance.
Farmers who use upgraded tarps to cover their fields while applying the pesticide can follow less stringent regulations,
said officials. Farmers use about 5 million pounds of the pesticide a year, most heavily in the Central Valley counties of San Joaquin and Fresno and along the coast in Monterey, Santa barbara, Santa cruz and Ventura counties.
The state has been talking with growers for more than a year about the new standards and will immediately begin implementing them,
with full compliance required by 2016. The state documented 787 people as suffering from exposure to the pesticide drifting through the air between 2002 and 2011, according to the most recent records.
In 2013,19 people picking raspberries in Monterey County were sickened, and in 2012,15 people in their homes and two firefighters near a Ventura County strawberry field reported irritated eyes, officials said.
California farmers fear that tighter restrictions will increase the costs of their fruits and vegetables,
potentially driving the market out of state or the country. Almond and grape growers use chloropicrin once every 20 to 30 years
when they plant a new orchard or vineyard, but California's strawberry growers, who use it each season,
California produces 88 percent of the nation's strawberry crop, supporting a $2. 3 billion industry,
It will cost the state's strawberry growers an estimated $20 million to buy upgraded tarps to cover their crops
"Farmers and their families live near their farms and work in their fields and care deeply about protecting the safety of their workers, neighbors and communities,
"O'Donnell said d
#Watching How Cells Interact The immune system is a complex network of many different cells working together to defend against invaders.
Successfully fighting off an infection depends on the interactions between these cells. A new device developed by MIT engineers offers a much more detailed picture of that cellular communication.
and collects data on each as they interact with each other, the researchers have learned already more about how T cells major players in the immune response become activated during infection.
The device is based on microfluidic technology developed by Joel Voldman an MIT professor of electrical engineering and computer science (EECS), in 2009.
His team used that earlier version to fuse adult cells with embryonic stem cells, allowing the researchers to observe the genetic reprogramming that occurred in these hybrids.
the paper lead author and a graduate student in EECS, spent several years re-engineering the device to get it to work with immune cells,
which are much smaller than the cells analyzed in 2009. Hidde Ploegh, an MIT professor of biology and member of the Whitehead Institute for Biomedical Research, is also a senior author of the paper.
Controlled contact Until now, the most common way to measure interactions between two types of cells was to mix the cells together in a test tube
The device consists of a chip with cell-trapping cups that are arranged strategically to capture
This technique allows the researchers to follow hundreds of cell pairs over time and monitor
a professor of chemical and biomolecular engineering at the Georgia Institute of technology who was involved not in the research. t very well-controlled
and display pieces of viral or bacterial proteins (known as antigens) on their cell surfaces. When these B cells encounter T cells with receptors that recognize the antigen,
the T cells become activated, provoking them to release cytokines inflammatory chemicals that control the immune response
the MIT team found that they did not all respond the same way after encountering B cells carrying identical antigens on their surfaces.
the researchers found that the initial activation level depends on how much of the antigen is presented. At high levels, most of the cells respond the same way.
at lower antigen levels, the T cell responses vary greatly. These differences also correlated to differences in T cell cytokine production.
#Scientists Create Device for Extracting Tumor Cells from Blood An international group led by scientists at UCLA California Nanosystems Institute has developed a new method for effectively extracting
Circulating tumor cells are cancer cells that break away from tumors and travel in the blood, looking for places in the body to start growing new tumors called metastases.
Capturing these rare cells would allow doctors to detect and analyze the cancer so they could tailor treatment for individual patients.
In his laboratory at the UCLA California Nanosystems Institute, Hsian-Rong Tseng a professor of molecular and medical pharmacology, used a device he invented to capture circulating tumor cells from blood samples.
The device, called the Nanovelcro Chip, is a postage-stampized chip with nanowires that are 1,
000 times thinner than a human hair and are coated with antibodies that recognize circulating tumor cells.
When 2 milliliters of blood are run through the chip, the tumor cells stick to the nanowires like Velcro.
Capturing the tumor cells was just part of the battle, though. To analyze them, Tseng team needed to be able to separate the cells from the chip without damaging them.
In earlier experiments with Nanovelcro the scientists used a technique called laser capture microdissection that was effective in removing individual cells from the chip without damaging them,
but the method was time-consuming and labor intensive, and it required highly specialized equipment.
Now Tseng and his colleagues have developed a thermoresponsive Nanovelcro purification system, which enables them to raise
and lower the temperature of the blood sample to capture (at 37 degrees Celsius) and release (at 4 degrees Celsius) circulating tumor cells at their optimal purity.
Polymer brushes on the Nanovelcro nanowires respond to the temperature changes by altering their physical properties allowing them to capture
or release the cells. Because it could make extracting the cancer cells much more efficient and cost-effective at a time in a patient life
when information is needed as quickly as possible, Tseng said it is conceivable that the new system will replace laser capture microdissection as the standard protocol. ith our new system,
we can control the blood temperature the way coffeehouses would with an espresso machine to capture
and then release the cancer cells in great purity, said Tseng, who is also a member of UCLA Jonsson Comprehensive Cancer Center. e combined the thermoresponsive system with downstream mutational analysis to successfully monitor the disease evolution of a lung cancer patient.
This shows the translational value of our device in managing nonmall-cell lung cancer with underlying mutations. r
#Biogen idec Columbia to Conduct Collaborative Genetics Research Biogen idec and Columbia University Medical center have formed a $30 million strategic alliance to conduct genetics discovery research on the underlying causes of disease
and to identify new treatment approaches. As part of this agreement, a sequencing and analysis facility and shared postdoctoral program will be established at Columbia to support collaborative genetics studies.
The agreement will integrate genomics research conducted at Columbia with Biogen idec understanding of disease mechanisms and pathways,
and expertise in discovering new medicines. ur understanding of human genetics is rapidly expanding, and there is growing recognition that the elucidation of the genetic causes of disease will have a transformative effect on both patient care
and drug development in many different diseases said David Goldstein, Phd, founding director of Columbia University Institute for Genomic medicine. his collaboration marries the exceptional drug development expertise of Biogen with cutting-edge genomics expertise at Columbia University Medical center.
It will not only focus on target identification and validation at the early stages of drug development,
but also facilitate genetically informed evaluation of treatments. uman genetic technologies and analytics have advanced to the point where they are becoming central to the discovery
and development of new medicines, said Tim Harris, Phd, DSC, Senior vice president, Technology and Translational Sciences,
Biogen idec. e are committed to working with leading institutions such as Columbia to advance basic genetic research and,
by combining our unique strengths, accelerating the discovery of potential new treatments. The collaboration will enable Biogen idec
and Columbia to investigate the genomes of patients showing unusual treatment responses or unique disease presentations and to explore the connections among genes, pathways,
and disease processes. The ultimate goal will be to provide multiple qualified targets for new therapeutic approaches,
increasing the potential for the development of new treatments. his collaboration with Biogen, with its focus on the genetic causes of diseases,
fits in perfectly with Columbia commitment to precision medicine, said Lee Goldman, MD, MPH, Harold and Margaret Hatch Professor of the University and dean of the faculties of health sciences and medicine. he development of new treatments based on this genetic understanding will have profound effects on clinical practice.
The new facility will have broad genetic research capabilities and the capacity to launch and complete whole-genome sequencing projects rapidly.
It will allow for rapid population-scale DNA sequencing across a broad range of disease areas, focusing on diseases with significant unmet clinical need such as amyotrophic lateral sclerosis (ALS) and idiopathic pulmonary fibrosis.
Tom Maniatis, Phd, the Isidore S. Edelman Professor of Biochemistry and chair of the Department of Biochemistry and Molecular Biophysics at Columbia University Medical center and director of Columbia university-wide
precision medicine initiative, said, he strong clinical and basic science programs in neurodegenerative diseases at Columbia will significantly benefit from the Columbia/Biogen alliance.
We expect that the alliance will dramatically advance our understanding of the genetics of these devastating diseases and ultimately lead to mechanism-based treatments, a key aspect of Columbia precision-medicine initiative. c
#Radiation Hormone Therapy Prolong Survival for Older Men With Prostate Cancer Adding radiation treatment to hormone therapy saves more lives among older men with locally advanced prostate therapy than hormone
therapy alone according to a new study in the Journal of Clinical Oncology from Penn Medicine researchers.
The researchers found that hormone therapy plus radiation reduced cancer deaths by nearly 50 percent in men aged 76 to 85 compared to men who only received hormone therapy.
Past studies have shown that 40 percent of men with aggressive prostate cancers are treated with hormone therapy alone exposing a large gap in curative cancer care among baby boomers aging into their 70s.#
#ailure to use effective treatments for older patients with cancer is a health care quality concern in the United states.#
#Radiation plus hormone therapy is such a treatment for men with aggressive prostate cancerssaid lead author Justin E. Bekelman MD an assistant professor of Radiation Oncology Medical Ethics and Health policy at Penn
Perelman School of medicine and Abramson Cancer Center.##atients and their physicians should carefully discuss curative treatment options for prostate cancer
and reduce the use of hormone therapy alone. ocally advanced prostate cancer is cancer that has spread outside but near the prostate gland.
Unlike slower growing tumors locally advanced prostate cancer is an aggressive malignancy that is prone to metastasize
and cause cancer deaths. Hormone therapy lowers or blocks the levels of testosterone and other androgens (male hormones) that feed prostate cancer tumors.
Two landmark clinical trials have shown that radiation plus hormone therapy produces a large and significant improvement in survival in younger men relative to hormone therapy alone
but until now there has been no comparable research on treatment for older men with advanced prostate cancer.
Addressing this question for the first time Penn research team compared the combination of radiation plus hormone therapy
versus hormone therapy alone among 31 541 men with prostate cancer ranging in age from 65 years to 85 years.
Among men age 65 to 75 years old radiation plus hormone therapy was associated with a reduction in prostate cancer deaths of 57 percent relative to hormone therapy alone
(from 9. 8 percent to 4. 4 percent of patients at 7 years follow up. Similarly among men age 76 to 85 years old radiation plus hormone therapy was associated with a reduction in prostate cancer deaths of 49 percent relative to hormone therapy alone
(from 9. 8 percent to 5. 0 percent of patients at 7 years follow-up. In both groups radiation plus hormone therapy was associated also with about one-third fewer deaths from any cause.
Importantly the clinical trials have shown that the side effects of radiation plus hormone therapy are very acceptable relative to hormone therapy alone. lder men with aggressive prostate cancers should know that the combination of radiation plus
hormone therapy is both tolerable and effective in curing prostate cancersaid Bekelman. In addition to offering new evidence for older men Bekelman research also demonstrates that the prior clinical trial findings for younger men apply in the eal-worldof routine clinical practice.#
#Only three percent of cancer patients participate in clinical trials; thus confirming that treatments work in real-world care is a crucial aspect of translating medical evidence to clinical practice.
Bekelman study is an example of patient-centered cancer comparative effectiveness research which provides reliable useful information to help individual patients make informed cancer care decisions
and improve cancer care outcomes. The Penn-led study examined radiation treatment and hormone therapy in the Surveillance Epidemiology and End Results (SEER) Medicare database.
SEER collects data from population-based cancer registries that cover 26 percent of the U s. population and Medicare
which covers 97 percent of the U s. population 65 years of age or older. Patients received treatments not by random assignment but as part of their normal clinical care.
Bekelman team utilized specialized analysis techniques to mimic randomized clinical trials in data from routine care
and to identify which treatments are best for men of different age groups and cancer severity e
Overtext Web Module V3.0 Alpha
Copyright Semantic-Knowledge, 1994-2011